心血管鈣化市場規模、佔有率和成長分析：按類型、診斷、治療、適應症、最終用戶和地區分類－2026-2033年產業預測

2024 年全球心血管鈣化市場價值為 13.8 億美元，預計到 2033 年將從 2025 年的 14.6 億美元成長至 65.2 億美元，預測期（2026-2033 年）複合年成長率為 5.9%。

全球心血管鈣化市場涵蓋一系列診斷、治療和醫療設備產品，旨在解決動脈鈣化問題。動脈鈣化與心臟衰竭、中風和周邊動脈疾病密切相關，並顯著增加醫療保健支出。隨著診斷影像技術的進步，該市場正在不斷發展，這使得冠狀動脈鈣化評分的精確計算成為可能，並促使製藥公司開發針對鈣沉積的標靶治療。近期成長主要得益於監管部門的批准，這些批准加快了保險覆蓋範圍，並獎勵醫院投資於CT和PET掃描等先進影像技術。這種轉變使得對心臟病高風險患者進行風險分層成為可能，並促進了醫療設備製造商和人工智慧公司之間的合作，從而推動創新訂閱模式的發展。此外，由於聯合治療試驗取得了令人鼓舞的結果，礦物質代謝療法也吸引了大量投資。

全球心血管鈣化市場成長要素

全球心血管鈣化市場的主要促進因素之一是心血管疾病盛行率的上升，這是一個全球性的健康問題。肥胖、糖尿病和高血壓等風險因素的日益增多，促使人們對旨在控制心血管鈣化的先進診斷和治療方案的需求不斷成長。此外，人們對早期發現和早期療育重要性的認知不斷提高，以及影像和治療方法的技術進步，都在推動市場成長。對更佳治療效果的追求和對有效管理策略的需求，也正在推動該領域的投資和創新。

全球心血管鈣化市場的限制因素

全球心血管鈣化市場的主要限制因素之一是先進診斷和治療技術的高昂成本。這些治療的經濟負擔可能導致醫療機構在投資最新設備和療法方面猶豫不決，從而限制患者獲得必要的醫療服務。此外，不同地區的保險報銷政策差異也會造成治療機會的不平等，尤其是在低收入市場。這種經濟障礙可能導致心血管鈣化疾病的漏診和治療不足，最終迫使相關人員優先考慮成本效益高的解決方案而非昂貴但先進的方案，這可能會阻礙市場成長和創新。

全球心血管鈣化市場趨勢

全球心血管鈣化市場呈現顯著上升趨勢，主要得益於雙能量CT和PET-MRI等精準影像技術的快速發展。這些創新提高了臨床醫生檢測微鈣化的能力，有助於風險分層和製定個人化治療方案。因此，製藥公司正將研發重點與基於影像的治療效果結合，最終更有效地最佳化治療方案。醫院增加對這些先進成像設備的投入以改善患者照護，而保險公司則預期透過早期診斷和減少侵入性手術來節省長期成本。因此，技術、醫療服務和經濟效益的整合正在心血管鈣化領域創造新的格局。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心血管鈣化市場規模：按類型分類

• 內膜鈣化
• 中層鈣化
• 心臟瓣膜鈣化

全球心血管鈣化市場規模：依診斷分類

• 診斷影像
  • 電腦斷層掃描（CT）
  • 心臟超音波圖
  • 磁振造影（MRI）
  • 其他
• 臨床實驗室檢測和生物標記檢測

全球心血管鈣化市場規模：依治療方法分類

• 藥物治療
• 介入治療
  • 經導管治療
  • 手術介入
• 支持性護理和風險因素管理

全球心血管鈣化市場規模：依適應症分類

• 冠狀動脈鈣化
• 主動脈瓣鈣化
• 周邊動脈鈣化
• 頸動脈鈣化
• 其他

全球心血管鈣化市場規模：依最終用戶分類

• 醫院
• 專科循環系統中心
• 診斷影像中心
• 門診手術中心

全球心血管鈣化市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Shockwave Medical Inc
• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Terumo Corporation
• Sanofi SA
• Novartis AG
• Pfizer Inc
• AstraZeneca plc
• Merck & Co Inc
• Bristol Myers Squibb Company
• GlaxoSmithKline plc
• Amgen Inc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Inozyme Pharma Inc
• Sanifit Therapeutics SA
• Cardialen Inc
• Vascular Pathways
• Calcimed

結論與建議

Global Cardiovascular Calcification Market size was valued at USD 1.38 Billion in 2024 and is poised to grow from USD 1.46 Billion in 2025 to USD 6.52 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The global cardiovascular calcification market encompasses a range of diagnostic, therapeutic, and medical device products aimed at addressing arterial calcification, a condition linked to heart failure, stroke, and peripheral arterial disease, which significantly increases healthcare expenditures. The market has evolved with advancements in diagnostic imaging technologies, enabling precise coronary calcium scoring and prompting pharmaceutical companies to create targeted treatments for calcium deposition. Recent growth is fueled by regulatory approvals, encouraging insurance coverage that incentivizes hospitals to invest in advanced imaging techniques like CT and PET scans. This shift enables risk stratification for patients at risk of cardiac issues, fostering collaborations between device manufacturers and AI companies for innovative subscription models, while mineral metabolism treatments garner investments due to promising clinical trial results for combination therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiovascular Calcification market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiovascular Calcification Market Segments Analysis

Global cardiovascular calcification market is segmented by type, diagnosis, treatment, indication, end user and region. Based on type, the market is segmented into Intimal Calcification, Medial Calcification and Valvular Calcification. Based on diagnosis, the market is segmented into Imaging Modalities and Laboratory & Biomarker Testing. Based on treatment, the market is segmented into Pharmacological Therapy, Interventional Procedures and Supportive & Risk Factor Management. Based on indication, the market is segmented into Coronary Artery Calcification, Aortic Valve Calcification, Peripheral Arterial Calcification, Carotid Artery Calcification and Others. Based on end user, the market is segmented into Hospitals, Specialty Cardiology Centers, Diagnostic Imaging Centers and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiovascular Calcification Market

One key market driver for the global cardiovascular calcification market is the rising prevalence of cardiovascular diseases, which has become a significant health concern worldwide. The increasing incidence of risk factors such as obesity, diabetes, and hypertension contributes to the growing demand for advanced diagnostic and therapeutic solutions aimed at managing cardiovascular calcification. Furthermore, heightened awareness about the importance of early detection and intervention, alongside technological advancements in imaging techniques and treatment modalities, is propelling market growth. The pursuit of better patient outcomes and the need for effective management strategies also drive investments and innovations in this sector.

Restraints in the Global Cardiovascular Calcification Market

One significant market restraint for the global cardiovascular calcification market is the high cost associated with advanced diagnostic and treatment technologies. The financial burden of these procedures can deter healthcare providers from investing in the latest equipment and therapies, limiting patient access to necessary care. Additionally, varying reimbursement policies across regions can create disparities in treatment availability, particularly in lower-income markets. This economic barrier may lead to underdiagnosis and undertreatment of cardiovascular calcification conditions, ultimately hindering market growth and innovation as stakeholders prioritize more cost-effective solutions over advanced, albeit expensive, options.

Market Trends of the Global Cardiovascular Calcification Market

The Global Cardiovascular Calcification market is experiencing a notable upward trend, driven by significant advancements in precision imaging technologies such as dual energy CT and PET MRI. These innovations enhance clinicians' ability to detect micro-calcifications, facilitating improved risk stratification and personalized treatment strategies. Consequently, pharmaceutical companies are aligning their development efforts with imaging-driven outcomes, ultimately tailoring therapies more effectively. Hospitals are increasingly investing in these sophisticated imaging machines to advance patient care, while insurers anticipate long-term cost reductions from early diagnoses and fewer invasive procedures. This convergence of technology, healthcare delivery, and economic efficiency is reshaping the cardiovascular calcification landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cardiovascular Calcification Market Size by Type & CAGR (2026-2033)

• Market Overview
• Intimal Calcification
• Medial Calcification
• Valvular Calcification

Global Cardiovascular Calcification Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging Modalities
  • Computed Tomography (CT)
  • Echocardiography
  • Magnetic Resonance Imaging (MRI)
  • Others
• Laboratory & Biomarker Testing

Global Cardiovascular Calcification Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
• Interventional Procedures
  • Transcatheter Interventions
  • Surgical Interventions
• Supportive & Risk Factor Management

Global Cardiovascular Calcification Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Coronary Artery Calcification
• Aortic Valve Calcification
• Peripheral Arterial Calcification
• Carotid Artery Calcification
• Others

Global Cardiovascular Calcification Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Cardiology Centers
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers

Global Cardiovascular Calcification Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, Indication, End User)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Shockwave Medical Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inozyme Pharma Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanifit Therapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardialen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vascular Pathways
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calcimed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations